Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Elraglusib + Gemcitabine + Nab-paclitaxel |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Elraglusib | 9 ING 41|9-ING-41 | GSK-3beta Inhibitor 4 | Elraglusib is an ATP-competitive inhibitor that selectively blocks GSK-3beta, potentially leading to cell cycle arrest and apoptosis, inhibition of tumor cell proliferation, and decreased tumor growth (PMID: 31894292, PMID: 29846250). | |
Gemcitabine | Gemzar | Difluorodeoxycytidine Hydrochlorothiazide|LY-188011 | Chemotherapy - Antimetabolite 14 | Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary). |
Nab-paclitaxel | Abraxane | ABI-007|Paclitaxel Protein-bound | Chemotherapy - Taxane 3 | Abraxane (nab-paclitaxel) is an albumin-stablized version of paclitaxel, which binds microtubules and prevents depolymerization, resulting in decreased cell motility and division (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03678883 | Phase Ib/II | Carboplatin + Elraglusib + Paclitaxel Elraglusib + Irinotecan Doxorubicin + Elraglusib Elraglusib + Lomustine Carboplatin + Elraglusib Elraglusib + Gemcitabine + Nab-paclitaxel Elraglusib Elraglusib + Gemcitabine | 9-ING-41 in Patients With Advanced Cancers | Active, not recruiting | USA | NLD | FRA | ESP | CAN | BEL | 1 |